Heat shock protein inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Heat Shock Protein (Hsp) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Heat Shock Protein (Hsp) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Heat Shock Protein (Hsp) Inhibitor: Overview
Heat Shock Proteins (HSPs) are a family of proteins that are transcriptionally upregulated under cellular stress including exposure to heat/ UV/ cold/pH changes, tissue remodeling etc. The HSPs are also called as 'chaperone' proteins as they bind and assist in correct protein folding and also help in refolding improperly folded proteins.
Function - Heat shock protein 90 (HSP90) is an important member of the chaperone protein family and it is involved in stabilization, regulation, and maintenance of oncogenic client proteins with co-chaperones. Cochaperones regulate the ATPase activity of HSP90 and its interactions with oncogenic client proteins. Therefore, HSP90 and its co-chaperones have become important therapeutic targets for cancer treatment. This has led to the development of several inhibitors of HSP90 and other HSPs that have shown promise both preclinically and clinically in the treatment of cancer.
Heat Shock Protein (Hsp) Inhibitor - An Hsp90 inhibitor is a substance that inhibits that activity of the Hsp90 heat shock protein. Since Hsp90 stabilizes a variety of proteins required for survival of cancer cells, these substances may have therapeutic benefit in the treatment of various types of malignancies. Furthermore, a number of Hsp90 inhibitors are currently undergoing clinical trials for a variety of cancers. Hsp90 inhibitors include the natural products geldanamycin and radicicol as well as semisynthetic derivatives.
Heat Shock Protein (Hsp) Inhibitor Emerging Drugs Chapters
This segment of the Heat Shock Protein (Hsp) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Heat Shock Protein (Hsp) Inhibitor Emerging Drugs
Further product details are provided in the report……..
Heat Shock Protein (Hsp) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Heat Shock Protein (Hsp) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
Heat Shock Protein (Hsp) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Heat Shock Protein (Hsp) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heat Shock Protein (Hsp) Inhibitor drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Heat Shock Protein (Hsp) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Heat Shock Protein (Hsp) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Heat Shock Protein (Hsp) Inhibitor: Overview
Heat Shock Proteins (HSPs) are a family of proteins that are transcriptionally upregulated under cellular stress including exposure to heat/ UV/ cold/pH changes, tissue remodeling etc. The HSPs are also called as 'chaperone' proteins as they bind and assist in correct protein folding and also help in refolding improperly folded proteins.
Function - Heat shock protein 90 (HSP90) is an important member of the chaperone protein family and it is involved in stabilization, regulation, and maintenance of oncogenic client proteins with co-chaperones. Cochaperones regulate the ATPase activity of HSP90 and its interactions with oncogenic client proteins. Therefore, HSP90 and its co-chaperones have become important therapeutic targets for cancer treatment. This has led to the development of several inhibitors of HSP90 and other HSPs that have shown promise both preclinically and clinically in the treatment of cancer.
Heat Shock Protein (Hsp) Inhibitor - An Hsp90 inhibitor is a substance that inhibits that activity of the Hsp90 heat shock protein. Since Hsp90 stabilizes a variety of proteins required for survival of cancer cells, these substances may have therapeutic benefit in the treatment of various types of malignancies. Furthermore, a number of Hsp90 inhibitors are currently undergoing clinical trials for a variety of cancers. Hsp90 inhibitors include the natural products geldanamycin and radicicol as well as semisynthetic derivatives.
Heat Shock Protein (Hsp) Inhibitor Emerging Drugs Chapters
This segment of the Heat Shock Protein (Hsp) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Heat Shock Protein (Hsp) Inhibitor Emerging Drugs
- Pimitespib (TAS 116): Taiho Pharmaceutical
- RTA 901: Reata Pharmaceuticals
Further product details are provided in the report……..
Heat Shock Protein (Hsp) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Heat Shock Protein (Hsp) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Heat Shock Protein (Hsp) Inhibitor
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Heat Shock Protein (Hsp) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Heat Shock Protein (Hsp) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heat Shock Protein (Hsp) Inhibitor drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Heat Shock Protein (Hsp) Inhibitor R&D. The therapies under development are focused on novel approaches for Heat Shock Protein (Hsp) Inhibitor.
- Heat Shock Protein (Hsp) Inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Heat Shock Protein (Hsp) Inhibitor drugs?
- How many Heat Shock Protein (Hsp) Inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Heat Shock Protein (Hsp) Inhibitor?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Heat Shock Protein (Hsp) Inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Heat Shock Protein (Hsp) Inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
- Taiho Pharmaceutical
- Reata Pharmaceuticals
- Soligenix
- Exelixis
- Third Coast Therapeutics
- Serenex
- Chia Tai Tianqing Pharmaceutical Group
- Wakamoto
- Samus Therapeutics
- Aldeyra Therapeutics
- Joseah Biopharma
- Novartis
- Vernalis
- Astex Pharmaceuticals
- Minneamrita Therapeutics
- RESprotect
- Pimitespib (TAS 116)
- RTA 901
- XL 888
- 3 crx 98
- SNX 5422
- TQB 3474
- WP 1303
- Zelavespib
- ADX-1612
- ADX-1615
- MPT0B640
- NVP BEP 800
- Onalespib
- Minnelide
- Brivudine
Introduction
Executive Summary
Heat Shock Protein (Hsp) Inhibitor: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Heat Shock Protein (Hsp) Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Heat Shock Protein (Hsp) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Heat Shock Protein (Hsp) Inhibitor Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Pimitespib: Taiho Pharmaceutical
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
SNX 5422: Serenex
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
RTA 901: Reata Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
NVP BEP 800: Vernalis
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Heat Shock Protein (Hsp) Inhibitor Key Companies
Heat Shock Protein (Hsp) Inhibitor Key Products
Heat Shock Protein (Hsp) Inhibitor- Unmet Needs
Heat Shock Protein (Hsp) Inhibitor- Market Drivers and Barriers
Heat Shock Protein (Hsp) Inhibitor- Future Perspectives and Conclusion
Heat Shock Protein (Hsp) Inhibitor Analyst Views
Heat Shock Protein (Hsp) Inhibitor Key Companies
Appendix
Executive Summary
Heat Shock Protein (Hsp) Inhibitor: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Heat Shock Protein (Hsp) Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Heat Shock Protein (Hsp) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Heat Shock Protein (Hsp) Inhibitor Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Pimitespib: Taiho Pharmaceutical
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
SNX 5422: Serenex
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
RTA 901: Reata Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
NVP BEP 800: Vernalis
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Heat Shock Protein (Hsp) Inhibitor Key Companies
Heat Shock Protein (Hsp) Inhibitor Key Products
Heat Shock Protein (Hsp) Inhibitor- Unmet Needs
Heat Shock Protein (Hsp) Inhibitor- Market Drivers and Barriers
Heat Shock Protein (Hsp) Inhibitor- Future Perspectives and Conclusion
Heat Shock Protein (Hsp) Inhibitor Analyst Views
Heat Shock Protein (Hsp) Inhibitor Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Heat shock protein inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Heat shock protein inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Heat shock protein inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Heat shock protein inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
